Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Novo (NVO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. If you purchased or otherwise acquired Novo shares and suffered a loss, are a long-term stockholder, have information, ...

Market Dynamics & Competition - Novo Nordisk's oral wegovy shows promising 16.6% weight loss with good tolerability, potentially shifting the oral market split [3][4] - The oral wegovy faces a "food effect" issue, requiring specific consumption conditions (fasting, water, waiting 30 minutes), potentially limiting its use to maintenance after initial weight loss with injectables [4][7] - Manufacturing costs for oral wegovy are higher due to the larger peptide dosage (25mg) compared to the weekly injectable (2.4mg) [7] - The weight loss drug space is experiencing pricing headwinds and some pricing concessions, potentially influenced by the CVS exclusive deal [8][9] Company Performance & Expectations - Lilly's stock experienced a significant drop (down 14%) due to data expectations being set too high (above 15% efficacy), raising questions about the long-term strength of their franchise [1][2] - There was a disconnect between Novo Nordisk's positive presentation of their data (27 pounds average weight loss) and the market's expectations [9] - Companies need to learn from competitors' successes and failures in managing expectations and messaging around drug data [13]

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/novo-nordisk-a-s-loss-submission-form-3/?id=159984&from=3 CLASS PERIOD: May 7, 2025 t ...

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S for allegedly providing misleading statements regarding its growth potential and market capabilities during the specified class period from May 7, 2025, to July 28, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Novo Nordisk made overly positive statements while concealing material adverse facts about its growth potential, particularly regarding the GLP-1 market [5]. - It is alleged that the company overstated the likelihood of patients switching to its branded alternatives and misrepresented its capability to penetrate the GLP-1 market [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering significant amounts for clients [4]. - Investors are advised to select qualified legal counsel with a proven history in similar cases, as not all firms have comparable experience [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

Group 1 - Novo Nordisk (NVO.US) shares rose nearly 6%, reaching $47.99 as of the report [1] - Eli Lilly (LLY.US) competitor's first small molecule oral GLP-1 drug, Orforglipron, achieved an average weight loss of 11.2%, which is below the expected range of 13% to 15% or more [1]

智通财经APP获悉，周四，诺和诺德(NVO.US)股价走高，截至发稿，该股涨近6%，报47.99美元。消息 面上，该公司竞争对手礼来(LLY.US)的首个小分子口服GLP - 1药物Orforglipron实现平均减重11.2%，低 于预期的13%至15%或更多。 ...

Core Viewpoint - Novo Nordisk's stock price increased by nearly 6% to $47.99 following news about a competitor's drug performance [1] Group 1: Company Performance - Novo Nordisk's stock price rose significantly, indicating positive market sentiment towards the company [1] - The competitor Eli Lilly's first oral GLP-1 drug, Orforglipron, achieved an average weight loss of 11.2%, which was below the expected range of 13% to 15% or more [1] Group 2: Market Reaction - The market reacted positively to Novo Nordisk's stock, reflecting investor confidence in its products compared to competitors [1] - The underperformance of Eli Lilly's drug may create a competitive advantage for Novo Nordisk in the GLP-1 market [1]

每经AI快讯，美股三大指数集体高开，道指涨0.59%，纳指涨0.77%，标普500指数涨0.5%。礼来跌超 9%，此前实验显示，礼来口服药物Orforglipron平均减重11.2%，低于预期；诺和诺德涨超6%。 ...

Novo Nordisk (NVO) Q2 2025 Earnings Call August 07, 2025 08:15 AM ET Company ParticipantsJames Quigley - Executive DirectorKarsten Knudsen - EVP, CFO & Member of the Management BoardLudovic Helfgott - EVP - Product & Portfolio StrategyDavid Moore - EVP - US OperationsMartin Lange - Executive VP - R&D and Chief Scientific OfficerJacob Martin Wiborg Rode - Head - IRThibault Boutherin - Executive Director - Equity ResearchSimon Baker - Partner & Head - Global Biopharma ResearchHarry Sephton - Director - Pharma ...

Group 1 - Novo Nordisk's Wegovy and Eli Lilly's Mounjaro saw sales in India double in July compared to June, indicating strong demand for these obesity treatments [1] - Wegovy's sales reached 5,000 units with a revenue of 70 million INR (approximately 797,000 USD), while Mounjaro's sales hit 157,000 units with a revenue of 470 million INR [1] - Novo Nordisk's Q2 sales were 76.857 billion DKK, a 13% year-over-year increase, with a net profit of 26.503 billion DKK, up 32% [2] Group 2 - Eli Lilly reported Q2 revenue of 15.6 billion USD, a year-over-year increase of approximately 38%, but faced challenges with its oral weight loss drug underperforming expectations [2] - Novo Nordisk is advancing its research on Amycretin for weight management and has initiated the REDEFINE11 study to explore CagriSema's potential [2] - As of the latest trading, Novo Nordisk's stock rose by 8% in pre-market, while Eli Lilly's stock fell by 7.8% [3]